Related Experiment Video
Updated: Aug 14, 2026
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
[CD34+ antigen expression relating to prognosis in acute myeloid leukemia]
1Department of Hematology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, China.
Insights
CD34 antigen expression in acute myeloid leukemia (AML) indicates a poorer prognosis. CD34-positive AML patients have a lower complete remission rate, highlighting CD34
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- CD34 is a cell surface glycoprotein expressed on hematopoietic stem cells and early progenitor cells.
- Understanding antigen expression aids in prognostication and treatment strategies for AML.
Purpose:
- To investigate the expression of CD34 antigen in newly diagnosed AML patients.
- To analyze the prognostic significance of CD34 expression in AML.
- To correlate CD34 expression with French-American-British (FAB) subtypes and complete remission (CR) rates.
Summary:
- CD34 antigen expression was detected in 38.7% of 238 AML patients using indirect immunofluorescence.
- CD34 positivity was associated with FAB subtypes M(0) and M(1), and absent in M(3) subtypes.
- CD34-positive AML patients exhibited a significantly lower CR rate (32%) compared to CD34-negative patients (61%).
- Increased expression of lymphoid-associated antigen CD7 was observed in CD34-positive AML patients.
Impact:
- CD34 antigen expression is a valuable biomarker for predicting poor prognosis in AML.
- The findings suggest that CD34 status can inform risk stratification and potentially guide therapeutic decisions in AML management.
- Further research into the role of CD34 and associated markers may improve outcomes for AML patients.
Abstract:
To explore CD34(+) antigen expression in new diagnosed acute myeloid leukemia (AML) and analyze the prognosis for CD34(+) AML patients, the expression of antigen CD34 in 238 AML patients was detected by indirect immunofluorescence assay. The results showed that CD34 in 92 out of the 238 patients (38.7%) were positive, there was relationship between the CD34(+) expression and FAB subtypes (M(0), M(1)), and no CD34(+) expression was observed in M(3) subtypes. The complete remission rate of CD34(+) AML patients was 32%, which was lower than that of CD34(-) AML (61%). The lymphoid-associated antigen (CD7) was significantly increased in CD34(+) AML patients, compared with CD34(-) patients (P < 0.05). It is concluded that CD34(+) AML patients show poor prognosis and lower CR rate. The detection of CD34 expression is of some value in predicting prognosis in AML.
